Markets
News
Analysis
User
24/7
Economic Calendar
Education
Data
- Names
- Latest
- Prev












Signal Accounts for Members
All Signal Accounts
All Contests



France Trade Balance (SA) (Oct)A:--
F: --
Euro Zone Employment YoY (SA) (Q3)A:--
F: --
Canada Part-Time Employment (SA) (Nov)A:--
F: --
P: --
Canada Unemployment Rate (SA) (Nov)A:--
F: --
P: --
Canada Full-time Employment (SA) (Nov)A:--
F: --
P: --
Canada Labor Force Participation Rate (SA) (Nov)A:--
F: --
P: --
Canada Employment (SA) (Nov)A:--
F: --
P: --
U.S. PCE Price Index MoM (Sept)A:--
F: --
P: --
U.S. Personal Income MoM (Sept)A:--
F: --
P: --
U.S. Core PCE Price Index MoM (Sept)A:--
F: --
P: --
U.S. PCE Price Index YoY (SA) (Sept)A:--
F: --
P: --
U.S. Core PCE Price Index YoY (Sept)A:--
F: --
P: --
U.S. Personal Outlays MoM (SA) (Sept)A:--
F: --
U.S. 5-10 Year-Ahead Inflation Expectations (Dec)A:--
F: --
P: --
U.S. Real Personal Consumption Expenditures MoM (Sept)A:--
F: --
U.S. Weekly Total Rig CountA:--
F: --
P: --
U.S. Weekly Total Oil Rig CountA:--
F: --
P: --
U.S. Consumer Credit (SA) (Oct)A:--
F: --
China, Mainland Foreign Exchange Reserves (Nov)A:--
F: --
P: --
Japan Trade Balance (Oct)A:--
F: --
P: --
Japan Nominal GDP Revised QoQ (Q3)A:--
F: --
P: --
China, Mainland Imports YoY (CNH) (Nov)A:--
F: --
P: --
China, Mainland Exports (Nov)A:--
F: --
P: --
China, Mainland Imports (CNH) (Nov)A:--
F: --
P: --
China, Mainland Trade Balance (CNH) (Nov)A:--
F: --
P: --
China, Mainland Exports YoY (USD) (Nov)A:--
F: --
P: --
China, Mainland Imports YoY (USD) (Nov)A:--
F: --
P: --
Germany Industrial Output MoM (SA) (Oct)A:--
F: --
Euro Zone Sentix Investor Confidence Index (Dec)A:--
F: --
P: --
Canada National Economic Confidence IndexA:--
F: --
P: --
U.K. BRC Like-For-Like Retail Sales YoY (Nov)--
F: --
P: --
U.K. BRC Overall Retail Sales YoY (Nov)--
F: --
P: --
Australia Overnight (Borrowing) Key Rate--
F: --
P: --
RBA Rate Statement
RBA Press Conference
Germany Exports MoM (SA) (Oct)--
F: --
P: --
U.S. NFIB Small Business Optimism Index (SA) (Nov)--
F: --
P: --
Mexico 12-Month Inflation (CPI) (Nov)--
F: --
P: --
Mexico Core CPI YoY (Nov)--
F: --
P: --
Mexico PPI YoY (Nov)--
F: --
P: --
U.S. Weekly Redbook Index YoY--
F: --
P: --
U.S. JOLTS Job Openings (SA) (Oct)--
F: --
P: --
China, Mainland M1 Money Supply YoY (Nov)--
F: --
P: --
China, Mainland M0 Money Supply YoY (Nov)--
F: --
P: --
China, Mainland M2 Money Supply YoY (Nov)--
F: --
P: --
U.S. EIA Short-Term Crude Production Forecast For The Year (Dec)--
F: --
P: --
U.S. EIA Natural Gas Production Forecast For The Next Year (Dec)--
F: --
P: --
U.S. EIA Short-Term Crude Production Forecast For The Next Year (Dec)--
F: --
P: --
EIA Monthly Short-Term Energy Outlook
U.S. API Weekly Gasoline Stocks--
F: --
P: --
U.S. API Weekly Cushing Crude Oil Stocks--
F: --
P: --
U.S. API Weekly Crude Oil Stocks--
F: --
P: --
U.S. API Weekly Refined Oil Stocks--
F: --
P: --
South Korea Unemployment Rate (SA) (Nov)--
F: --
P: --
Japan Reuters Tankan Non-Manufacturers Index (Dec)--
F: --
P: --
Japan Reuters Tankan Manufacturers Index (Dec)--
F: --
P: --
Japan Domestic Enterprise Commodity Price Index MoM (Nov)--
F: --
P: --
Japan Domestic Enterprise Commodity Price Index YoY (Nov)--
F: --
P: --
China, Mainland PPI YoY (Nov)--
F: --
P: --
China, Mainland CPI MoM (Nov)--
F: --
P: --


No matching data
Latest Views
Latest Views
Trending Topics
Top Columnists
Latest Update
White Label
Data API
Web Plug-ins
Affiliate Program
View All

No data
German business confidence unexpectedly dipped in November, a fresh sign of the challenge to overcome stagnation even as the government ramps up spending.
German business confidence unexpectedly dipped in November, a fresh sign of the challenge to overcome stagnation even as the government ramps up spending.
An expectations index by the Ifo institute dropped to 90.6 in November from 91.6 the previous month, a release Monday showed. Analysts in a Bloomberg survey had predicted an unchanged reading. A measure of existing conditions edged higher.
"Companies assessed their current situation as somewhat more positive," Ifo President Clemens Fuest said. "They have little faith that a recovery is coming anytime soon," however, with the outlook among manufacturers taking a "significant hit."
The data underscore doubts about the government's plan to restore growth by investing in infrastructure and defense. While the Bundesbank and most other forecasters expect output to expand in the fourth quarter after a volatile 2025, some have recently scaled back their predictions.
Chancellor Friedrich Merz's economic advisers this month lowered their growth forecast for next year to less than 1%, while warning that the government must ensure outlays are targeted at additional and productive investments. Otherwise, the chance to address deep-seated challenges and restore longer-term growth could be squandered, they said.
Business surveys by S&P Global released last week showed business activity continued to grow in November, but at a slower pace than in the previous month. Manufacturing suffered a particular setback as new orders fell sharply.
The European Commission still said last week that it expects Germany to end its long period of stagnation next year. While US tariffs and global uncertainty will continue to pressure exporters, the economy should benefit from higher investments and private consumption next year, it said.
![Best Trading Platform for Beginners to Pros [2025]_1 Best Trading Platform for Beginners to Pros [2025]_1](https://img.fastbull.com/prod/image/2025/11/4F721A9A8E2D4A0B81385B19F5882C4C.jpeg)
In 2025, choosing the best trading platform is no longer just about low fees. Beginners and professional traders now look for speed, safety, smart tools, and easy access to global markets. This guide helps you understand what truly defines the best trading platform, compare key features, and select an option that matches your trading style, risk level, and long-term investment goals.
Finding the best trading platform is not just about popularity. It should match your experience level, trading style, and the markets you want to access. While some traders focus on stocks and ETFs, others look for the best crypto trading platform or broader access to cryptocurrencies.
| Factor | Why It Matters |
|---|---|
| Fees | Directly affect long-term profitability |
| Market Access | Allows flexibility across different assets |
| Security | Protects user funds and personal data |
For new traders, the best trading platform should be simple, low-risk, and supportive. Many best online trading platforms focus on easy navigation and guided learning to help users start confidently.
eToro is often chosen by beginners who want a balance between ease of use and exposure to multiple markets.
Webull offers a realistic paper trading environment that allows new users to test strategies without risking real money. This makes it ideal for practising market entry and exit timing.
Robinhood is designed for ease and convenience, making it appealing to users who trade mainly through smartphones.
Intermediate traders move beyond basics and focus on execution quality, analysis tools, and cost efficiency. At this stage, traders may also explore the best trading platform cryptocurrency for broader diversification.
Plus500 is well-suited for traders who place frequent trades and require responsive systems.
thinkorswim stands out for traders who rely heavily on data-driven decisions and deep market research.
| Feature | Benefit |
|---|---|
| Options strategy tools | Improves trade planning accuracy |
| Custom analytics | Detailed performance insights |
| Clear fee structure | Better cost visibility |
tastytrade is popular among traders seeking structured options trading with predictable costs and strong analytics.
Advanced traders prioritize precision, speed, and deep market control. At this level, the best trading platform is one that supports complex strategies, large trade volumes, and access to global instruments, including advanced crypto markets.
Interactive Brokers is widely recognised among professionals who need tight spreads, real-time data, and stable performance under high trading pressure, making it one of the most trusted best online trading platforms.
| Margin Feature | Trader Advantage |
|---|---|
| Low interest rates | Reduces leverage cost |
| Simple pricing model | Clear cost structure |
| Flexible account tiers | Adaptable risk control |
DEGIRO appeals to traders who actively use leverage and seek lower borrowing costs without sacrificing platform reliability.
Saxo Bank is often chosen by those managing international portfolios or searching for the best trading platform cryptocurrency for diversified global exposure.
With so many platforms available, finding the best trading platform requires a clear and structured approach. Your decision should be based on how you trade, what you trade, and how much you’re willing to pay for access and performance.
Many traders focus only on commissions, but real costs go far beyond that.
| Cost Type | What to Review |
|---|---|
| Trading fees | Per trade or spread-based pricing |
| Funding costs | Overnight or margin interest |
| Conversion fees | Costs for multi-currency trading |
Testing helps confirm whether a platform truly fits your trading habits, whether you are aiming for equities, forex, or the best cryptocurrency trading platform experience.
Legit platforms are regulated by authorities like FCA, ASIC, or SEC and show clear licensing, transparent fees, and strong user reviews.
The safest platforms use fund segregation, encryption, and strict compliance rules to protect user assets.
It is possible but very hard for most traders and usually requires large capital and high risk.
Choosing the best trading platform depends on your experience, goals, and risk tolerance. Beginners should focus on simplicity and safety, while advanced traders need speed and deep market access. By comparing fees, features, and real performance, you can find a best trading platform that supports steady growth and smarter long-term trading decisions.
Bayer's experimental stroke drug could generate €3 billion in annual sales after successful trial results that Goldman Sachs analyst James Quigley called "transformational" for the German pharmaceutical company's business.
Shares of the company were up 8.9% at 03:20 ET (08:20 GMT).
The drugmaker announced on Sunday that asundexian met its primary goals in the OCEANIC-STROKE trial, significantly reducing the risk of repeat strokes without increasing major bleeding rates compared to a placebo.
Both treatments were given alongside standard antiplatelet therapy in more than 12,300 patients who had previously experienced a non-cardioembolic ischemic stroke or high-risk transient ischemic attack.
Quigley said removing the risk adjustment from his valuation model leads to a roughly 13% increase in his discounted cash flow analysis.
He noted this positive result is the first of two developments that could help narrow the gap between Bayer's current share price and the value of its business units.
The second event, a potential recommendation from the solicitor general on a glyphosate legal case, is expected in the coming weeks.
The trial addresses a significant medical problem. Approximately 12 million people worldwide experience strokes each year, with 20% to 30% being recurrent strokes. One in five stroke survivors will have another stroke within five years.
Stroke ranks as the second leading cause of death globally, and recurrent ischemic strokes tend to be more disabling and carry higher mortality risks than initial strokes.
"Even with currently available therapies, the risk of another stroke remains high, and each recurrence can have profound consequences," said Mike Sharma, the principal investigator from the Population Health Research Institute at McMaster University and director of the Stroke Program at Hamilton Health Sciences in a statement.
Asundexian works by blocking Factor XIa, a protein in the blood coagulation pathway. The Leverkusen-based company said Factor XIa plays a minor role in forming hemostatic plugs that seal vessel injuries but contributes to blood clot growth and vessel blockage.
The drugmaker theorizes asundexian reduces clot formation without significantly increasing major bleeding risk.
Patients in the multicenter, randomized, double-blind trial received either 50 mg of asundexian once daily or a placebo, both combined with antiplatelet therapy.
This marks the first time a drug in the Factor XIa inhibitor class has successfully completed a Phase III study.
The U.S. Food and Drug Administration granted asundexian Fast Track Designation as a potential treatment for stroke prevention in patients after a non-cardioembolic ischemic stroke. The compound has not been approved by any health authority for use in any country.
White Label
Data API
Web Plug-ins
Poster Maker
Affiliate Program
The risk of loss in trading financial instruments such as stocks, FX, commodities, futures, bonds, ETFs and crypto can be substantial. You may sustain a total loss of the funds that you deposit with your broker. Therefore, you should carefully consider whether such trading is suitable for you in light of your circumstances and financial resources.
No decision to invest should be made without thoroughly conducting due diligence by yourself or consulting with your financial advisors. Our web content might not suit you since we don't know your financial conditions and investment needs. Our financial information might have latency or contain inaccuracy, so you should be fully responsible for any of your trading and investment decisions. The company will not be responsible for your capital loss.
Without getting permission from the website, you are not allowed to copy the website's graphics, texts, or trademarks. Intellectual property rights in the content or data incorporated into this website belong to its providers and exchange merchants.
Not Logged In
Log in to access more features

FastBull Membership
Not yet
Purchase
Log In
Sign Up